Clinical Trial: A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)

U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07850609) titled 'A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)' on Sept. 23.

Brief Summary: The goal of this study is to learn about the safety of alimatravir (MK-8527) in transgender and gender-diverse people and if they tolerate it.

Study Start Date: Oct. 29

Study Type: INTERVENTIONAL

Condition: HIV

Intervention: DRUG: Alimatravir

11 mg tablets taken orally once monthly (qm) for a total of 3 doses

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Merck Sharp & Dohme LLC

Pu...